Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma: Clinical article

Journal of Neurosurgery

Volumn 111, Issue 3, 2009, Pages 497-503

  Hill Jr , Kenneth L ^a   Lipson, Adam C ^a   Sheehan, Jonas M ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Breast carcinoma; Metastasis; Peritumoral edema; Renal cell carcinoma; Sorafenib; Sunitinib

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 2; SORAFENIB; SUNITINIB; SUTANT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN METASTASIS; BRAIN SURGERY; BREAST CARCINOMA; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DRUG EXTRAVASATION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMAGE ANALYSIS; INFLAMMATION; KIDNEY CARCINOMA; MALE; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SEIZURE; BRAIN; BRAIN TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BRAIN; BRAIN EDEMA; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDINES; PYRROLES; SEIZURES;

EID: 70350507465     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2008.7.JNS08143     Document Type: Article

References (15)

1. Adams VR, Leggas M: Sunitinib malate for the treatment of metastatic carcinoma and gastrointestinal stromal tumors. Clin Ther 29:1338-1353, 2007 (Pubitemid 47348120)
2. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM: Influence of breast cancer resistance protein (Abcg2) and pglycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 102:1749-1757, 2007 (Pubitemid 47329285)
3. Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, et al: Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 73:338-348, 2008 (Pubitemid 351159204)
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
5. Goodman VL, Rock EP, Dgher R, Ramchandani RP, Abraham S, Gobburur JV, et al: Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367-1373, 2007 (Pubitemid 46450424)
6. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI: Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 24:e48, 2006
7. Grandinetti CA, Goldspiel BR: Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 27:1125-1144, 2007 (Pubitemid 47173659)
8. Harada Y, Nonomura N, Kondo M, Nishimura K, Takahara S, Miki T, et al: Clinical study of brain metastasis of renal cell carcinoma. Eur Urol 36:230-235, 1999 (Pubitemid 29381310)
9. Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, et al: Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 111:523-530, 2008
10. Martín G, Bellido L, Cruz JJ: Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25:3559, 2007 (Letter) (Pubitemid 47310905)
11. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003 (Pubitemid 36109749)
12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
13. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006 (Pubitemid 43854967)
14. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006 (Pubitemid 46630627)
15. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004 (Pubitemid 39331023)